Provided by Tiger Trade Technology Pte. Ltd.

Denali Therapeutics Inc.

24.92
-0.0300-0.12%
Post-market: 24.920.00000.00%19:30 EDT
Volume:680.99K
Turnover:16.96M
Market Cap:3.98B
PE:-8.79
High:25.37
Open:25.25
Low:24.60
Close:24.95
52wk High:27.30
52wk Low:12.58
Shares:159.85M
Float Shares:151.07M
Volume Ratio:0.67
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8353
EPS(LYR):-2.9700
ROE:-54.93%
ROA:-29.15%
PB:4.77
PE(LYR):-8.39

Loading ...

Denali regains full rights to DNL593 after Takeda ends collaboration

Reuters
·
Apr 04

Denali Therapeutics Regains Full Rights to Investigational Therapy Dnl593 (Ptv:Pgrn) for Grn-Related Frontotemporal Dementia (Ftd-Grn)

THOMSON REUTERS
·
Apr 04

Denali Therapeutics Inc - to Continue Clinical Development of Dnl593 Using Transportvehicle Technology

THOMSON REUTERS
·
Apr 04

Denali Therapeutics Inc - Results From Phase 1/2 Study in Ftd-Grn Expected by End of 2026

THOMSON REUTERS
·
Apr 04

FDA grants accelerated approval to Denali’s tividenofusp alfa

Reuters
·
Apr 01

Denali Therapeutics Inc - Receives $200 Mln in Gross Proceeds on March 27, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 31

Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition?

Simply Wall St.
·
Mar 30

Stifel Nicolaus Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

TIPRANKS
·
Mar 30

Wedbush Remains a Buy on Denali Therapeutics (DNLI)

TIPRANKS
·
Mar 26

US FDA Approves Avlayah To Treat Neurologic Manifestations Of Hunter Syndrome

Reuters
·
Mar 26

BUZZ-Denali Therapeutics climbs after US FDA approves co's genetic disorder therapy

Reuters
·
Mar 26

US FDA approves Denali's genetic disorder therapy for children

Reuters
·
Mar 25

Denali Therapeutics granted FDA approval of AVLAYAH for treatment of MPS II

TIPRANKS
·
Mar 25

Denali Therapeutics gains FDA accelerated approval for AVLAYAH in Hunter syndrome; CSF heparan sulfate drops 91% by week 24

Reuters
·
Mar 25

Denali Therapeutics Announces U.S. FDA Approval of Avlayah™ (Tividenofusp Alfa-Eknm) for Treatment of Hunter Syndrome (Mps Ii)

THOMSON REUTERS
·
Mar 25

Denali Therapeutics Inc - Avlayah to Be Available in U.S. Shortly After Approval, Administered Once Weekly

THOMSON REUTERS
·
Mar 25

Denali Therapeutics Inc - Awarded Rare Pediatric Disease Priority Review Voucher With FDA Approval

THOMSON REUTERS
·
Mar 25

Denali Therapeutics Shares up 4.4%; US FDA Approves Co's Genetic Disorder Therapy

THOMSON REUTERS
·
Mar 25

US FDA - Approves Avlayah to Treat Neurologic Manifestations of Hunter Syndrome

THOMSON REUTERS
·
Mar 25

Wedbush Remains a Buy on Denali Therapeutics (DNLI)

TIPRANKS
·
Mar 23